SEC Form 4 · accession 0001415889-16-007484
INNOVUS PHARMACEUTICALS, INC. · INNV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Hoffman
Officer — CHIEF FINANCIAL OFFICER
Period of report
Sep 6, 2016
Accepted (ET)
Nov 21, 2016 · 6:00 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411879
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock unitsF1,F2 | — | Sep 6, 2016 | A | 2,500,000 | A | Nov 16, 2016 | Nov 16, 2026 | Common Stock | 2,500,000 | 2,500,000 | D |
Explanation of responses
- F1Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- F2The Reporting Person was granted a Restricted Stock Unit on September 6, 2016 of 2,500,000 shares, which shall vest according to the following schedule: 1/3 after one year of employment with the Issuer and then in equal quarterly increments over the next eight quarters upon continuous employment with the Company.
- F3These restricted stock units were granted pursuant to the Issuer's 2016 Equity Incentive Plan.